Latest News-Harbour Biomed Mediaroom_Page

Harbour BioMed Announces NMPA Approval of IND for Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Treatment of NSCLC and Solid Tumors

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Feb. 26, 2021 /PRNewswire/ -- Harbou...

2021-02-26 10:16 6988

Harbour BioMed's Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 28, 2021 /PRNewswire/ -- Harbour B...

2021-01-28 12:54 6768

Harbour BioMed Completes Its Global Offering and Listing on the Hong Kong Stock Exchange

CAMBRIDGE, Mass. and SUZHOU, China, Dec. 17, 2020 /PRNewswire/ -- HBM Holdings Limited ("Harbour ...

2020-12-17 08:19 10620

Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials

CAMBRIDGE, Mass., SUZHOU, China, UTRECHT, Netherlands, Dec. 15, 2020 /PRNewswire/ -- Harbour BioMed...

2020-12-15 08:00 7799

HBM Holdings Limited Announces the Offer Price and Allotment Results of the Global Offering

This press release is NOT for release, publication, distribution, directly or indirectly, in or int...

2020-12-09 17:29 6295

Harbour BioMed Will Present Results From Its Phase II Clinical Trial with Tanfanercept (HBM9036) in Patients with Moderate-to-Severe Dry Eye Disease in China at the 25th Congress of Chinese Ophthalmological Society

SUZHOU, China, Nov. 16, 2020 /PRNewswire/ -- Harbour BioMed (HBM), a global, clinical-stage, bio-ph...

2020-11-16 20:17 3230

Harbour BioMed Announces Dosing of First Patients in Two Phase II Clinical Studies of Batoclimab (HBM9161) for the Treatment of Myasthenia Gravis and Immune Thrombocytopenia

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 30, 2020 /PRNewswire/ -- Harbo...

2020-09-30 21:50 5508

Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Harbo...

2020-09-21 20:12 4052

Harbour BioMed and Hualan Genetic Announced Collaboration to Develop Multiple Innovative Antibody Programs

CAMBRIDGE, Mass., ROTTERDAM, Netherlands, SUZHOU,China and XINXIANG, China, Sept. 11, 2020 /PRNewsw...

2020-09-11 21:33 7785

Harbour BioMed Presented Its Newly Discovered Anti-Human CCR8 Novel Monoclonal Antibodies at the 16th PEGS Boston 2020

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, Sept. 2, 2020 /PRNewswire/ -- Harbour Bi...

2020-09-02 11:40 3945

Harbour BioMed Will Present Its New Platform HBICE (Heavy chain only antibody (HCAb) Based Immune Cell Engager) at 16th PEGS Boston Summit

SHANGHAI, Aug. 31, 2020 /PRNewswire/ -- Harbour BioMed, a global, clinical-stage, innovative biopha...

2020-08-31 21:39 4490

Harbour BioMed Signs Strategic Collaboration Agreement with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Aug. 24, 2020 /PRNewswire/ -- Harbou...

2020-08-24 19:00 3643

Harbour BioMed Presented Its Newly Discovered BCMA x CD3 Bispecific Antibody at Cell Engager Summit 2020

CAMBRIDGE, Mass., ROTTERDAM, Netherlands, and SUZHOU, China, Aug. 21, 2020 /PRNewswire/ -- Harbour ...

2020-08-21 21:31 7402

Harbour BioMed, Utrecht University, Erasmus Medical Center, Viroclinics-DDL and Kiadis Pharma Announce Collaboration to Develop Monoclonal Antibody, Natural Killer Cell Combination Approach to Treating COVID-19

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Aug. 19, 2020 /PRNewswire/ -- Harbou...

2020-08-19 19:43 3246

Harbour BioMed Announces Strategic Partnership with Viva Biotech to Collaborate on Incubating Innovative Biotech Start-ups

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, SHANGHAI, China, July 31, 2020 /PRNewswire/...

2020-07-31 08:56 5680

Harbour BioMed Presented Pre-Clinical Data on A Fully Human Anti-CD73 Antibody at AACR Virtual Annual Meeting

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, July 16, 2020 /PRNewswire/ -- Harbour Bi...

2020-07-16 18:00 4265

Harbour BioMed Appoints Dr. Jon Wigginton to its Scientific Advisory Board

CAMBRIDGE, Mass, ROTTERDAM, Netherlands...

2020-06-11 18:00 4729

Harbour BioMed Appoints Dr. Jon Wigginton to its Scientific Advisory Board

Harbour BioMed Announces First Patient Dosing of Phase 1b/2a Study of Anti-FcRn Batoclimab for Treating Neuromyelitis Optica Spectrum Disorder

* First anti-FcRn PoC study for the treatment of NMOSD * Anti-FcRn antibody with potential to be...

2020-04-21 17:00 3283